Burr Sarah E, Camara Bully, Oluwalana Claire, Bojang Ebrima, Bottomley Christian, Bojang Abdoulie, Bailey Robin L, D'Alessandro Umberto, Roca Anna
London School of Hygiene and Tropical Medicine, London, UK.
Medical Research Council Unit, The Gambia, Fajara, Banjul, The Gambia.
BMC Infect Dis. 2017 Dec 28;17(1):799. doi: 10.1186/s12879-017-2909-4.
Vertical transmission can result in neonatal infection and disease. Reducing the transmission of bacterial pathogens from mother to infant may be an effective means of preventing neonatal infection, including bacterial conjunctivitis.
In a double-blind, randomized trial, we assessed the effect of administering a single dose of oral azithromycin to women in labour on bacterial colonization of the neonate. A reduction in purulent neonatal conjunctivitis was a secondary objective of the trial. Ocular samples were collected from the lower fornix of infants presenting with clinical signs of purulent conjunctivitis during the first eight weeks of life. Incidence of purulent conjunctivitis was compared between trial arms. Bacterial infection was assessed using PCR and incidence of purulent conjunctivitis due to bacteria was also compared between arms.
Forty of 843 infants (4.7%) presented clinical signs of purulent conjunctivitis. No significant difference in incidence of purulent conjunctivitis was seen between azithromycin and placebo arms [4.3% (18/419) versus 5.2% (22/424), OR = 0.82, 95% CI (0.44,1.54), p = 0.628]. S. aureus was the most commonly identified pathogen, detected in 38% of cases. Incidence of purulent-conjunctivitis due to bacterial infection was lower in the azithromycin arm [1.2% (5/419) versus 3.8% (16/424), OR = 0.31, 95% CI (0.12-0.82), p = 0.025)]. The incidence of gram-positive bacteria was also lower in the azithromycin arm [1.0% (4/419) versus 3.3% (14/424), OR = 0.28, 95%CI (0.10-0.82), p = 0.029].
Oral azithromycin given to women during labour may have the potential to reduce the incidence of bacterial neonatal conjunctivitis.
ClinicalTrials.gov, identifier NCT01800942 , registration date 26 Feb 2013.
垂直传播可导致新生儿感染和疾病。减少细菌病原体从母亲传播至婴儿可能是预防新生儿感染(包括细菌性结膜炎)的有效手段。
在一项双盲随机试验中,我们评估了在分娩时给女性单次口服阿奇霉素对新生儿细菌定植的影响。脓性新生儿结膜炎发病率的降低是该试验的次要目标。在出生后前八周内,从出现脓性结膜炎临床症状的婴儿下穹窿采集眼部样本。比较试验组间脓性结膜炎的发病率。使用聚合酶链反应(PCR)评估细菌感染情况,并比较试验组间由细菌引起的脓性结膜炎发病率。
843名婴儿中有40名(4.7%)出现脓性结膜炎的临床症状。阿奇霉素组和安慰剂组脓性结膜炎发病率无显著差异[4.3%(18/419)对5.2%(22/424),比值比(OR)=0.82,95%置信区间(CI)(0.44,1.54),p = 0.628]。金黄色葡萄球菌是最常鉴定出的病原体,在38%的病例中检测到。阿奇霉素组中因细菌感染导致的脓性结膜炎发病率较低[1.2%(5/419)对3.8%(16/424),OR = 0.31,95%CI(0.12 - 0.82),p = 0.025]。阿奇霉素组革兰氏阳性菌的发病率也较低[1.0%(4/419)对3.3%(14/424),OR = 0.28,95%CI(0.10 - 0.82),p = 0.029]。
分娩时给女性口服阿奇霉素可能有降低新生儿细菌性结膜炎发病率的潜力。
ClinicalTrials.gov,标识符NCT01800942,注册日期2013年2月26日。